Evidence map›Paper›PMID 34965023›Full record

ArticleClinical and translational medicine2021

Claudin-2 promotes colorectal cancer growth and metastasis by suppressing NDRG1 transcription.

Mingtian Wei, Yaguang Zhang, Xuyang Yang, Pingfan Ma, Yan Li, Yangping Wu, Xiangzheng Chen, Xiangbing Deng, Tinghan Yang, Xiaobing Mao and 5 more

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Insight into the Regulation of NDRG1 Expression.International journal of molecular sciences · 2025
    Review
  15. Roles of LncRNA ARSR in tumor proliferation, drug resistance, and lipid and cholesterol metabolism.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Mingtian WeiDepartment of Gastrointestinal Surgery, Frontiers Science Center for Disease-related Molecular Network and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Yaguang ZhangResearch Laboratory of Tumors Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Xuyang YangDepartment of Gastrointestinal Surgery, Frontiers Science Center for Disease-related Molecular Network and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Pingfan MaResearch Laboratory of Tumors Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yan LiResearch Laboratory of Tumors Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yangping WuDepartment of Respiratory and Critical Care Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xiangzheng ChenDepartment of Liver Surgery & Liver Transplantation Center, West China Hospital, Sichuan University, Chengdu, China.
Xiangbing DengDepartment of Gastrointestinal Surgery, Frontiers Science Center for Disease-related Molecular Network and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Tinghan YangDepartment of Gastrointestinal Surgery, Frontiers Science Center for Disease-related Molecular Network and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Xiaobing MaoResearch Laboratory of Tumors Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Lei QiuResearch Laboratory of Tumors Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Wenjian MengDepartment of Gastrointestinal Surgery, Frontiers Science Center for Disease-related Molecular Network and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Bo ZhangDepartment of Gastrointestinal Surgery, Frontiers Science Center for Disease-related Molecular Network and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Ziqiang WangDepartment of Gastrointestinal Surgery, Frontiers Science Center for Disease-related Molecular Network and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
Junhong HanResearch Laboratory of Tumors Epigenetics and Genomics, Department of General Surgery, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-3371-8698
Sichuan University · CN

Funding

1·3·5 Project for Disciplines of Excellence, West China Hospital ZYGD180031·3·5 Project for Disciplines of Excellence, West China Hospital ZYJC21021China Postdoctoral Science Foundation 2017M612961Foundation for Innovative Research Groups of the National Natural Science Foundation of China 81821002National Key Research and Development Program of China 2018YFC1312300National Natural Science Foundation of China 31972884National Natural Science Foundation of China 81172373Sichuan Province Science and Technology Support Program 2019YFS0375Young Scientific Scholarship Foundation of Sichuan University 2017SCU11029
6 · The paper itself

Abstract

Colorectal cancer (CRC) is one of the most common malignant tumours, with multiple driving factors and biological transitions involved in its development. Claudin-2 (CLDN2), a well-defined component of cellular tight junction, has been indicated to associate with CRC progression. However, the function of CLDN2 and the underlying mechanism whereby the downstream signalling transduction is regulated in CRC remains largely unclear. In this study, we demonstrated that CLDN2 is upregulated in CRC samples and associated with poor survival. And CLDN2 depletion significantly promotes N-myc downstream-regulated gene 1 (NDRG1) transcription, leading to termination of the CRC growth and metastasis in vitro and in vivo. Mechanistically, this process promotes CLDN2/ZO1/ZONAB complex dissociation and ZONAB shuttle into nucleus to enrich in the promoter of NDRG1. Thus, this study reveals a novel CLDN2/ZO1/ZONAB-NDRG1 axis in CRC by regulating the expression of EMT-related genes and CDKIs, suggesting CLDN2 may serve as a promising target for CRC treatment.

Indexed as

Cell Cycle ProteinsCell Line, TumorClaudin-2Colorectal NeoplasmsHumansIntracellular Signaling Peptides and ProteinsNeoplasm MetastasisN-myc Downstream-Regulated Gene 1 ProteinCell Cycle ProteinsClaudin-2Intracellular Signaling Peptides and ProteinsN-myc Downstream-Regulated Gene 1 ProteinCLDN2colorectal cancerNDRG1progressionZONAB

Identifiers

PMID34965023
PMCPMC8715829
OpenAlexW4200355917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.